# Cannabidiol for ASD Open Trial

> **NCT03900923** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 29 (actual)

## Conditions studied

- ASD
- Autism Spectrum Disorder

## Interventions

- **DRUG:** 98% pure CBD

## Key facts

- **NCT ID:** NCT03900923
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-12
- **Primary completion:** 2023-05-04
- **Final completion:** 2023-05-04
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03900923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03900923, "Cannabidiol for ASD Open Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03900923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*